Today at #Target25, we presented interim clinical data from the phase 2 trial of petosemtamab in combination with standard of care FOLFOX/FOLFIRI in 1L and 2L metastatic colorectal cancer (mCRC) and petosemtamab monotherapy in 3L+ mCRC #CloseInOnCancer #ColorectalCancer ir.merus.nl/news-release...
Interim data on petosemtamab presented today at #Targets25 demonstrate a robust response rate and a favorable, well-tolerated safety profile in metastatic colorectal cancer.
Petosemtamab, a bispecific antibody targeting EGFR x LGR5, is designed to employ 3 distinct mechanisms of action: -Inhibition of EGFR ligand binding and downstream signaling -Degradation of EGFR via LGR5 internalization -Engagement of host immune cells via ADCP and enhanced ADCC #CloseInOnCancer
Petosemtamab, a bispecific antibody targeting EGFR x LGR5, is designed to employ 3 distinct mechanisms of action - Inhibition of EGFR ligand binding and downstream signaling - Degradation of EGFR via LGR5 internalization - Engagement of host immune cells via ADCP and enhanced ADCC #CloseInOnCancer
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics ir.merus.nl/news-release...
Merus’ plenary session oral presentation on petosemtamab in metastatic colorectal cancer will be on October 24, 10:00 -11:40 a.m. ET at #Targets25. The poster on the preclinical evaluation of petosemtamab on cancer stem cells will be on October 24, 12:30-4:00 p.m. ET. ir.merus.nl/news-release...
New talent. Same mission. When we succeed, we give patients with cancer access to medicines that could change their lives. We’re excited to welcome our new team members. If you want to be part of something bigger, now is the time. Join us. #CloseInOnCancer
On #WorldCancerResearchDay, we stand united with researchers around the world working towards new treatments and improved outcomes for patients living with cancer. #CloseInOnCancer
Petosemtamab, a bispecific antibody targeting EGFR x LGR5, is designed to employ three distinct MOAs: - Inhibition of EGFR ligand binding and downstream signaling - Degradation of EGFR via LGR5 internalization - Engagement of host immune cells via ADCP and enhanced ADCC
Innovation drives progress – and meaningful progress comes when new therapies are both efficacious and safe. On #WorldPatientSafetyDay, and every day, we reaffirm our commitment to making patient safety a cornerstone in the development of new potential treatments for cancer. #CloseInOnCancer
Petosemtamab is a novel and highly innovative bispecific antibody in development for Head and Neck cancer and Colorectal cancer, with a unique mechanism of action. www.mdpi.com/2072-6694/17...
Stay tuned to learn more about petosemtamab’s unique mechanism of action.
Our CEO Bill Lundberg will participate in a fireside chat today at the Wells Fargo Healthcare Conference. The presentation will be available on our Investors page and for a limited time thereafter.
Welcome Bharti, Matthew, and Deitmar! With multiple therapeutic candidates in the clinic, we’re building momentum toward our goal of becoming a leading oncology company. If you’re looking for a place where your work has real meaning, join us careers.merus.nl #CloseInOnCancer
We are proud to be developing petosemtamab, with its unique biology designed to have three distinct mechanisms of action: EGFR ligand blocking, EGFR receptor internalization and degradation in LGR5+ cells, and Fc-mediated activation of the innate immune system. lnkd.in/eyGQrTpF #CloseInOnCancer
Our CEO Bill Lundberg will participate in a fireside chat today at Canaccord Genuity’s 45th Annual Growth Conference. The presentation will be available on our Investors page and for a limited time thereafter.
During the day, we’re #ClosingInOnCancer. After hours and on weekends, we’re hitting the road. Whether mountain biking in the local forests and flower fields or raising money for worthy causes, Merus cyclists ride with passion and dedication. And yes, we even have our own Merus cycling apparel!
When the lab coats come off and the computers shut down, the thinking caps stay on. Meet the Merus Pub Quiz crew, a highly competitive group of colleagues participating in local trivia nights. It's just one of the ways we stay connected – and sharp – when we’re off the clock.
Barbara is a member of the Clinical Operations team, where she drives clinical research forward by coordinating trial logistics, leading site management activities, and managing patient recruitment, all while prioritizing patient safety.
Our CEO Bill Lundberg will participate in a fireside chat today at the Jefferies Global Healthcare Conference. The presentation will be available on our Investors page and for a limited time thereafter.
Kimberli is a clinical scientist. Her team works collaboratively with the trial team to review and interpret complex clinical data to ensure data integrity. The path from discovery to treatment is powered by people who ask the right questions and know how to find the answers, every day.
We're proud to share updated interim clinical data on petosemtamab with pembrolizumab in first line PD-L1+ r/m #HNSCC. The data in the poster is reported in our press release: ir.merus.nl/news-release...
We're sharing updated interim clinical data on petosemtamab with pembrolizumab in first line PD-L1+ r/m #HNSCC. In 43 evaluable patients, a confirmed 63% response rate per investigator was observed. See the full presentation on our website. merus.nl/technology/p...
We’re thrilled to welcome Brenda, Shelly, and Quimby to our team! Now is an exciting time to be part of Merus. We’re growing, we’re hiring, and we’re making an impact. Interested in joining us? Explore our opportunities at careers.merus.nl. #CloseInOnCancer#Hiring#LifeAtMerus#WelcomeToTheTeam
